Bitwise launched the first US spot NEAR ETF on September 29, 2026, which now holds about 15.7 million NEAR tokens valued at $79.2 million. The fund attracted $35.5 million on its first day and $52.8 million by the end of its first week, reflecting strong investor demand. Unlike futures-based products, this ETF directly holds NEAR tokens and plans to stake a significant portion to earn rewards, potentially offsetting its 0.75% management fee. This launch expands regulated crypto exposure options for US investors, coinciding with NEAR's strategic focus on AI infrastructure and cross-chain capabilities.
Bitwise's NEAR ETF holds about 15.7 million NEAR tokens valued at $79.2 million two weeks after its launch. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Oct 15, 2026 00:11 WIB: out of 50 major cryptocurrencies priced on Pluang, 6 rose and 43 fell today. Notable movers include SAND at Rp1.004 with a 1-day change of -6.75%, ONE at Rp28 with -6.13%, and AXS at Rp19.411 with -5.03%.
Jefferies has maintained a Buy rating on Big Yellow Group despite recent stock declines, citing the company's strong fundamentals including freehold properties and solid cash flows. Activist investor Ancora, holding over 4% of shares, is pushing Big ...
Fastenal reported strong Q3 2026 earnings, beating analyst expectations with EPS of $0.35 and revenue of $2.46 billion. The company saw a 20% rise in net income to $401.6 million and a 15.5% increase in revenue driven by robust manufacturing demand, ...
Remittix announced the public launch of its RTX token on November 24, 2026, marking the end of its presale phase which raised over $32 million from 40,000 participants. The project is testing its PayFi platform, which enables crypto-to-fiat and fiat-...
The global microbiology testing market is projected to grow rapidly at a compound annual growth rate (CAGR) of approximately 9% from 2026 to 2034, reaching a market size of $13.7 billion by 2034. This growth is driven by the rising prevalence of infe...
H.C. Wainwright raised its price target for Alector from $5.00 to $8.00, maintaining a Buy rating due to progress in its neurodegenerative disease pipeline. Alector develops treatments for Alzheimer's and Parkinson's using its Brain Carrier platform ...
